Insights on Immunotherapy for Advanced Bladder Cancer - priME Oncology

Insights on Immunotherapy for Advanced Bladder Cancer

A Step Forward in Patient Care

Not a member of My prIME? Join now for instant access.

Enhance your understanding of the use of immunotherapy in advanced bladder cancer with videos from our satellite symposium at the ESMO Immuno Oncology Congress 2017 in Geneva. The biological basis for checkpoint inhibition in cancer treatment is discussed as well as the current treatment options for advanced bladder cancer. Furthermore, the faculty panel discusses patient cases, explaining how treatment providers can apply clinical trial data to real clinical practice.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Jan 19, 2018

Expiration Date

Jan 19, 2019

The biological basis for checkpoint inhibition in cancer treatment

Featured Expert: Aristotle Bamias, MD, PhD

A giant leap in the treatment options for advanced bladder cancer

Featured Expert: Yohann Loriot, MD, PhD

Q & A session

Featured Expert: Thomas Powles, MBBS, MRCP, MD

Interactive case-based panel discussion

Featured Expert: Thomas Powles, MBBS, MRCP, MD

prIME Points™


  • Thomas Powles, MBBS, MRCP, MDBarts Cancer Institute
    Queen Mary University of London
    London, United Kingdom


  • Aristotle Bamias, MD, PhDNational and Kapodistrian University of Athens
    Athens, Greece
  • Yohann Loriot, MD, PhDGustave Roussy
    Villejuif, France

This educational activity is specifically designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with urothelial cancers.

After successful completion of this educational activity, participants should be able to:

  • Describe the molecular basis for immunotherapy in cancers, including the function of immune checkpoints in the presence and absence of cancers
  • Examine the current evidence of the role of biomarkers and how to apply them in clinical practice
  • Explain the unique patterns of response to immunotherapy
  • Identify immune-related adverse events and strategies to manage them
  • Examine clinical trial findings for immune checkpoint inhibitors in advanced urothelial cancers
  • Describe the rationale for combination therapies of immunotherapeutic agents with each other, with chemotherapy, and with targeted agents

This educational activity is supported by a grant from F. Hoffmann-La Roche Ltd.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This enduring activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.